🎉 M&A multiples are live!
Check it out!

CG Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for CG Oncology and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

CG Oncology Overview

About CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.


Founded

2010

HQ

United States of America
Employees

113

Website

cgoncology.com

Financials

LTM Revenue $1.8M

LTM EBITDA -$130M

EV

$787M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

CG Oncology Financials

CG Oncology has a last 12-month revenue of $1.8M and a last 12-month EBITDA of -$130M.

In the most recent fiscal year, CG Oncology achieved revenue of $1.1M and an EBITDA of -$115M.

CG Oncology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See CG Oncology valuation multiples based on analyst estimates

CG Oncology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.2M $1.1M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$55.4M -$115M XXX XXX XXX
EBITDA Margin -27173% -10064% XXX XXX XXX
Net Profit -$35.4M -$48.6M XXX XXX XXX
Net Margin -17374% -4268% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

CG Oncology Stock Performance

As of April 15, 2025, CG Oncology's stock price is $20.

CG Oncology has current market cap of $1.5B, and EV of $787M.

See CG Oncology trading valuation data

CG Oncology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$787M $1.5B XXX XXX XXX XXX $-1.52

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

CG Oncology Valuation Multiples

As of April 15, 2025, CG Oncology has market cap of $1.5B and EV of $787M.

CG Oncology's trades at 435.7x LTM EV/Revenue multiple, and -6.1x LTM EBITDA.

Analysts estimate CG Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for CG Oncology and 10K+ public comps

CG Oncology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $787M XXX XXX XXX
EV/Revenue 691.1x XXX XXX XXX
EV/EBITDA -6.9x XXX XXX XXX
P/E -17.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -10.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get CG Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

CG Oncology Valuation Multiples

CG Oncology's NTM/LTM revenue growth is 1697%

CG Oncology's revenue per employee for the last fiscal year averaged $10K, while opex per employee averaged $1.0M for the same period.

Over next 12 months, CG Oncology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate CG Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for CG Oncology and other 10K+ public comps

CG Oncology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 458% XXX XXX XXX XXX
EBITDA Margin -10064% XXX XXX XXX XXX
EBITDA Growth 107% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -8368% XXX XXX XXX XXX
Revenue per Employee $10K XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 2959% XXX XXX XXX XXX
R&D Expenses to Revenue 7208% XXX XXX XXX XXX
Opex to Revenue 10167% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

CG Oncology Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

CG Oncology M&A and Investment Activity

CG Oncology acquired  XXX companies to date.

Last acquisition by CG Oncology was  XXXXXXXX, XXXXX XXXXX XXXXXX . CG Oncology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by CG Oncology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About CG Oncology

When was CG Oncology founded? CG Oncology was founded in 2010.
Where is CG Oncology headquartered? CG Oncology is headquartered in United States of America.
How many employees does CG Oncology have? As of today, CG Oncology has 113 employees.
Who is the CEO of CG Oncology? CG Oncology's CEO is Mr. Arthur Kuan.
Is CG Oncology publicy listed? Yes, CG Oncology is a public company listed on NAS.
What is the stock symbol of CG Oncology? CG Oncology trades under CGON ticker.
When did CG Oncology go public? CG Oncology went public in 2024.
Who are competitors of CG Oncology? Similar companies to CG Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of CG Oncology? CG Oncology's current market cap is $1.5B
What is the current revenue of CG Oncology? CG Oncology's last 12-month revenue is $1.8M.
What is the current EBITDA of CG Oncology? CG Oncology's last 12-month EBITDA is -$130M.
What is the current EV/Revenue multiple of CG Oncology? Current revenue multiple of CG Oncology is 435.7x.
What is the current EV/EBITDA multiple of CG Oncology? Current EBITDA multiple of CG Oncology is -6.1x.
What is the current revenue growth of CG Oncology? CG Oncology revenue growth between 2023 and 2024 was 458%.
Is CG Oncology profitable? Yes, CG Oncology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.